UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
------------
SCHEDULE 13G/A
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 2)
Regeneron Pharmaceuticals Inc.
--------------------------------------------------------------------------------
(Name of Issuer)
Common stock
--------------------------------------------------------------------------------
(Title of Class of Securities)
75886F107
--------------------------------------------------------------------------------
(CUSIP Number)
November 8, 2005
--------------------------------------------------------------------------------
(Date of Event Which Required Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this
Schedule is filed:
[ ] Rule 13d-1(b)
[X] Rule 13d-1(c)
[ ] Rule 13d-1(d)
---------------------------------
CUSIP No. 75886F107 13G/A Page 2 of 6 Pages
---------------------------------
-------- -----------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
NOVARTIS PHARMA AG
00-0000000
-------- -----------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) |_|
(b) |_|
-------- -----------------------------------------------------------------------
3 SEC USE ONLY
-------- -----------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
SWITZERLAND
---------------------------- ------ --------------------------------------------
NUMBER OF SHARES 5 SOLE VOTING POWER
0
------ --------------------------------------------
BENEFICIALLY OWNED BY SHARED VOTING POWER
6 0
------ --------------------------------------------
EACH REPORTING SOLE DISPOSITIVE POWER
7 0
------ --------------------------------------------
PERSON WITH SHARED DISPOSITIVE POWER
8 0
-------- -----------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
0
-------- -----------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
CERTAIN SHARES |_|
-------- -----------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
0
-------- -----------------------------------------------------------------------
12 TYPE OF REPORTING PERSON
CO
-------- -----------------------------------------------------------------------
---------------------------------
CUSIP No. 75886F107 13G/A Page 3 of 6 Pages
---------------------------------
Item 1(a). Name of Issuer:
Regeneron Pharmaceuticals Inc.
Item 1(b). Address of Issuer's Principal Executive Offices:
777 Old Saw Mill River Road
Tarrytown, NY 10591-6707
Item 2(a). Name of Person Filing:
Novartis Pharma AG
Item 2(b). Address of Principal Business Office or, if none, Residence:
Lichtstrasse 35
CH-4002, Basel
Switzerland
Item 2(c). Citizenship:
Switzerland
Item 2(d). Title of Class of Securities:
Common stock
Item 2(e). CUSIP Number:
75886F107
Item 3. If this statement is filed pursuant to Rules 13d-1(b), or
13d-2(b) or (c), check whether the person filing is a:
(a) |_| Broker or dealer registered under section 15 of the
Act;
(b) |_| Bank as defined in section 3(a)(6) of the Act;
(c) |_| Insurance company as defined in section 3(a)(19) of
the Act;
(d) |_| Investment company registered under section 8 of the
Investment Company Act of 1940;
(e) |_| An investment adviser in accordance with Rule
13d-1(b)(1)(ii)(E);
(f) |_| An employee benefit plan or endowment fund in
accordance with Rule 13d-1(b)(1)(ii)(F);
---------------------------------
CUSIP No. 75886F107 13G/A Page 3 of 6 Pages
---------------------------------
(g) |_| A parent holding company or control person in
accordance with Rule 13d-1(b)(1)(ii)(G) (Note: See
Item 7);
(h) |_| A savings association as defined in section 3(b) of
the Federal Deposit Insurance Act;
(i) |_| A church plan that is excluded from the definition of
an investment company under section 3(c)(14) of the
Investment Company Act of 1940;
(j) |_| Group, in accordance with Rule 13d-1(b)(1)(ii)(H).
If this statement is filed pursuant to Rule 13d-1(c), check
this box. |X|
Item 4. Ownership.
(a) Amount beneficially owned: Zero.
(b) Percent of class: Zero.
(c) Number of shares as to which the person has:
(i) sole power to vote or to direct the vote: Zero.
(ii) shared power to vote or to direct the vote: Zero.
(iii) sole power to dispose or to direct the disposition of:
Zero.
(iv) shared power to dispose or to direct the disposition
of: Zero.
Item 5. Ownership of Five Percent or Less of a Class.
If this statement is being filed to report the fact that as of
the date hereof the reporting person has ceased to be the
beneficial owner of more than five percent of the class of
securities, check the following [X].
Item 6. Ownership of More than Five Percent on Behalf of Another
Person.
Not applicable.
Item 7. Identification and Classification of the Subsidiary Which
Acquired the Security Being Reported on by the Parent Holding
Company or Control Person.
Not applicable.
Item 8. Identification and Classification of Members of the Group.
Not Applicable.
---------------------------------
CUSIP No. 75886F107 13G/A Page 3 of 6 Pages
---------------------------------
Item 9. Notice of Dissolution of Group.
Not Applicable.
Item 10. Certification.
Not applicable.
---------------------------------
CUSIP No. 75886F107 13G/A Page 3 of 6 Pages
---------------------------------
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
Dated: November 10, 2005
NOVARTIS PHARMA AG
By: /s/ Joseph E. Mamie
--------------------------------------
Name: Joseph E. Mamie
Title: Head of Operational Treasury
By: /s/ Christina Ackermann
--------------------------------------
Name: Christina Ackermann
Title: Head of Legal General Medicine